InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Compass Therapeutics, Inc.

CMPX Clue Score31
United States Fiscal year ends December CIK 0001738021
$0.99 +0.98% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.99 −70.79% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 5 Apr 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2019Operating income−0.0Net income−0.0Fiscal year 2019Operating income−34.1Net income−34.7Fiscal year 2020Operating income−0.0Net income−0.0Fiscal year 2020Operating income−27.8Net income−29.5Fiscal year 2021Operating income−81.9Net income−82.2Fiscal year 2022Operating income−41.7Net income−39.2Fiscal year 2023Revenue0.0Operating income−50.4Net income−42.5Fiscal year 2024Revenue0.9Operating income−56.6Net income−49.4Fiscal year 2025Revenue0.0 −100.0%Operating income−72.8Net income−66.5
FY2019FY2019FY2020FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a n/a n/a n/a 0.0 0.9 0.0
Growth −100.0%
Operating income −0.0 −34.1 −0.0 −27.8 −81.9 −41.7 −50.4 −56.6 −72.8
Net income −0.0 −34.7 −0.0 −29.5 −82.2 −39.2 −42.5 −49.4 −66.5
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2019Fiscal year 2019Fiscal year 2020Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Operating margin−6,661.8%Net margin−5,808.8%Free cash flow margin−5,282.2%Fiscal year 2025
FY2019FY2019FY2020FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a n/a n/a n/a −6,661.8% n/a
Net margin n/a n/a n/a n/a n/a n/a n/a −5,808.8% n/a
Free cash flow margin n/a n/a n/a n/a n/a n/a n/a −5,282.2% n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow−0.0Fiscal year 2019Operating cash flow−31.7Capital expenditure−0.5Free cash flow−32.2Fiscal year 2020Operating cash flow−0.0Fiscal year 2020Operating cash flow−26.8Capital expenditure−0.1Free cash flow−26.9Fiscal year 2021Operating cash flow−19.7Capital expenditure−1.6Free cash flow−21.2Fiscal year 2022Operating cash flow−34.1Capital expenditure−0.2Free cash flow−34.3Fiscal year 2023Operating cash flow−40.6Capital expenditure−0.0Free cash flow−40.6Fiscal year 2024Operating cash flow−44.9Capital expenditure−0.0Free cash flow−44.9Fiscal year 2025Operating cash flow−49.1Capital expenditure−0.0Free cash flow−49.2
FY2019FY2019FY2020FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −0.0 −31.7 −0.0 −26.8 −19.7 −34.1 −40.6 −44.9 −49.1
Capital expenditure n/a −0.5 n/a −0.1 −1.6 −0.2 −0.0 −0.0 −0.0
Free cash flow n/a −32.2 n/a −26.9 −21.2 −34.3 −40.6 −44.9 −49.2
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2019Cash0.0Shareholders’ equity−0.1Fiscal year 2019Cash25.3Total debt14.9Net cash (debt)10.4Shareholders’ equity11.3Debt to equity1.32Fiscal year 2020Cash0.0Shareholders’ equity−0.1Fiscal year 2020Cash47.1Total debt9.3Net cash (debt)37.7Shareholders’ equity39.9Debt to equity0.23Fiscal year 2021Cash144.5Total debt0.0Net cash (debt)144.5Shareholders’ equity140.1Debt to equity0.00Fiscal year 2022Cash34.9Shareholders’ equity181.6Fiscal year 2023Cash24.2Shareholders’ equity148.5Fiscal year 2024Cash43.5Shareholders’ equity125.2Fiscal year 2025Cash30.6Shareholders’ equity196.8
FY2019FY2019FY2020FY2020FY2021FY2022FY2023FY2024FY2025
Cash 0.0 25.3 0.0 47.1 144.5 34.9 24.2 43.5 30.6
Total debt n/a 14.9 n/a 9.3 0.0 n/a n/a n/a n/a
Net cash (debt) n/a 10.4 n/a 37.7 144.5 n/a n/a n/a n/a
Shareholders’ equity −0.1 11.3 −0.1 39.9 140.1 181.6 148.5 125.2 196.8
Debt to equity n/a 1.32 n/a 0.23 0.00 n/a n/a n/a n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Mar 2019 FY2019 31 Dec 2019 FY2020 31 Mar 2020 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−0.0 −31.7 −0.0 −26.8 −19.7 −34.1 −40.6 −44.9 −49.1
Growth
n/a 2.1 n/a 2.4 0.6 n/a n/a n/a n/a
Investment
n/a −0.5 n/a −0.1 −1.6 −0.2 −0.0 −0.0 −0.0
calc n/a −32.2 n/a −26.9 −21.2 −34.3 −40.6 −44.9 −49.2
Growth
calc n/a n/a n/a n/a n/a n/a n/a −0.33 n/a
n/a −0.5 n/a 0.0 −1.8 −151.2 27.0 46.8 −93.3
Financing
0.0 n/a 0.0 48.5 118.6 75.8 2.9 17.3 129.6

Lines marked calc are worked out here from filed figures; point at one for how. Capital expenditure, dividends and buybacks are shown as money out, so negative.